Skip to Content

Join the 'Revlimid' group to help and get support from people like you.

Revlimid News

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

FDA Expands Indication for Revlimid (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Posted 28 Feb 2017 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE) February 22,2017 – Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded indication ...

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to ...

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

New Drug Elotuzumab Shows Potential for Blood Cancer

Posted 2 Jun 2015 by Drugs.com

TUESDAY, June 2, 2015 – A two-pronged immune-boosting drug could provide new hope for people stricken with multiple myeloma, a cancer of the blood and bone marrow, according to clinical trial findings. The experimental drug, elotuzumab, reduced the risk of cancer progression and death by 30 percent when doctors combined it with the standard two-drug therapy for multiple myeloma, researchers ...

FDA Expands Indication for Revlimid (lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma

Posted 18 Feb 2015 by Drugs.com

SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). Revlimid plus dexamethasone was previously approved in June 2006 for use in ...

Too Few Prostate Cancer Patients Get Bone-Strengthening Meds: Study

Posted 3 Dec 2014 by Drugs.com

TUESDAY, Dec. 2, 2014 – Many men on hormone therapy for prostate cancer aren't getting bone-strengthening drugs they may need, new Canadian research contends. Hormone therapy, which suppresses male hormones called androgens, helps stop cancer cells from growing. But one consequence of the treatment is weakening of the bones, which can lead to fractures. To reduce this risk, men can be given oral ...

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be ...

Newer Drug Helps Myeloma Patients Who Can't Have Transplant

Posted 3 Sep 2014 by Drugs.com

WEDNESDAY, Sept. 3, 2014 – A cancer drug that targets the immune system may help improve the outlook for older adults with multiple myeloma, though a stem cell transplant remains the standard of care for relatively younger patients. Those are some of the findings from two studies in the Sept. 4 issue of the New England Journal of Medicine. Multiple myeloma is a cancer that begins in certain ...

FDA Approves Revlimid (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

Posted 5 Jun 2013 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013-- Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for Revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. “There rem ...

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the ...

New Drug Shows Promise for Myeloma Patients

Posted 9 May 2012 by Drugs.com

WEDNESDAY, May 9 – Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or getting chemotherapy. However, what isn't clear from the studies is whether or not the improved "progression-free" survival time will translate to a longer overall ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma, Myelodysplastic Diseases, Lymphoma, Anemia, Mantle Cell Lymphoma

Revlimid Patient Information at Drugs.com